Glenmark Pharmaceuticals
Reco price: Rs 312
Target price: Rs 343
Glenmark reported strong sales growth of 34.5 per cent YoY, ahead of analysts and street estimates driven by US, EU and RoW formulation segments. The disappointment came in from the high-margin domestic segment, which grew by mere 11.3 per cent YoY, impacted by inventory rationalisation. The company also incurred higher R&D cost during the quarter. In spite of strong rupee depreciation, Glenmark reported recurring operating margin of 18.0 per cent, well below estimates. Pinc Research has cut its FY13 earning estimates by three per cent to factor in higher R&D expenses which are offset by lower tax rate. Downgrade to Accumulate.

Pinc Research

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets end flat - SAIL to add 5 mn tonne capacity in FY13 - NHPC FY12 net up 28% at Rs 2,772 cr - Aarti Industries Q4 up nearly 27% at Rs 28.24 crore - BPCL posts four-fold jump in Q4 net at Rs 3,963 cr

Tags : Glenmark Pharmaceuticals | US | EU | RoW formulation segments |   Read Business news in  Advertisements -  Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol. -  Journey on, We are by Your Side. Click here to know more -  2 Lac Apartments, 1 Lac House / Plots. Click here -  Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol. -  Watch The Film Here. Click here to know more.. -  Leader in Passenger Car & Automobile Tyres. Click here -  1 billion in saving for Unilever without any tangles. -  A Brand New Server at a Price That Fits Your Budget. Click here -  Learn How One City is Running on FOOD SCRAPS. -  One Partnership Endless Possibilities. Click here to know more -  Helping doctors detect diseases earlier, saving costs & extending lives. -  36 Lakhs can get you a pool of Luxuries. Click here -  Which is the best plan for your daughter -  Check out the TRUE COLOURS of your Stocks, Now for FREE! -  One of the leading business schools in the world.Know More